Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1995 Sep;116(2):1821–1828. doi: 10.1111/j.1476-5381.1995.tb16669.x

Phosphoramidon inhibition of the in vivo conversion of big endothelin-1 to endothelin-1 in the human forearm.

C Plumpton 1, W G Haynes 1, D J Webb 1, A P Davenport 1
PMCID: PMC1909108  PMID: 8528566

Abstract

1. The vasoconstrictor peptide, endothelin-1 (ET-1) and a biologically inactive C-terminal fragment (CTF) are generated from an intermediate big ET-1 by a putative ET converting enzyme, sensitive to phosphoramidon. We have developed a procedure using selective solid-phase extraction and specific radioimmunoassays to measure the levels of immunoreactive (IR) big ET-1 and the products of conversion (ET-1 and CTF) in human plasma. These techniques have been used to determine the levels of the three peptides in venous plasma following local infusions of ET-1 and big ET-1, both alone and together with phosphoramidon. 2. Infusion of ET-1 into the brachial artery (5 pmol min-1) significantly increased (P < 0.05) IR ET levels from a basal level of 2.3 pM to 55.2 pM in plasma from the infused arm after 60 min of infusion. This corresponded with a marked decrease in forearm blood flow from a basal level of 2.6 ml dl-1 min-1 to 1.7 ml dl-1 min-1. The levels of IR big ET-1 and CTF were unchanged. Co-infusion of phosphoramidon (30 nmol min-1) with ET-1 had no significant effect on the plasma IR levels of ET, big ET-1, CTF, or blood flow. 3. Big ET-1 (50 pmol min-1) significantly increased (P < 0.05) venous concentrations of all three IR peptides after 60 min compared to basal (ET: from 2.2 to 7.7 pM, big ET-1; from 0 to 386.0 pM, CTF: from 0.2 to 37.0 pM).(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
1821

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ahlborg G., Ottosson-Seeberger A., Hemsén A., Lundberg J. M. Big ET-1 infusion in man causes renal ET-1 release, renal and splanchnic vasoconstriction, and increased mean arterial blood pressure. Cardiovasc Res. 1994 Oct;28(10):1559–1563. doi: 10.1093/cvr/28.10.1559. [DOI] [PubMed] [Google Scholar]
  2. Bennett T., Gardiner S. M. Recent developments in endothelin research. J Hum Hypertens. 1994 Aug;8(8):587–592. [PubMed] [Google Scholar]
  3. Clarke J. G., Benjamin N., Larkin S. W., Webb D. J., Davies G. J., Maseri A. Endothelin is a potent long-lasting vasoconstrictor in men. Am J Physiol. 1989 Dec;257(6 Pt 2):H2033–H2035. doi: 10.1152/ajpheart.1989.257.6.H2033. [DOI] [PubMed] [Google Scholar]
  4. Davenport A. P., Ashby M. J., Easton P., Ella S., Bedford J., Dickerson C., Nunez D. J., Capper S. J., Brown M. J. A sensitive radioimmunoassay measuring endothelin-like immunoreactivity in human plasma: comparison of levels in patients with essential hypertension and normotensive control subjects. Clin Sci (Lond) 1990 Mar;78(3):261–264. doi: 10.1042/cs0780261. [DOI] [PubMed] [Google Scholar]
  5. Davenport A. P., Maguire J. J. Is endothelin-induced vasoconstriction mediated only by ETA receptors in humans? Trends Pharmacol Sci. 1994 Jan;15(1):9–11. doi: 10.1016/0165-6147(94)90120-1. [DOI] [PubMed] [Google Scholar]
  6. Davenport A. P., Nunez D. J., Hall J. A., Kaumann A. J., Brown M. J. Autoradiographical localization of binding sites for porcine [125I]endothelin-1 in humans, pigs, and rats: functional relevance in humans. J Cardiovasc Pharmacol. 1989;13 (Suppl 5):S166–S170. doi: 10.1097/00005344-198900135-00045. [DOI] [PubMed] [Google Scholar]
  7. Davenport A. P., O'Reilly G., Kuc R. E. Endothelin ETA and ETB mRNA and receptors expressed by smooth muscle in the human vasculature: majority of the ETA sub-type. Br J Pharmacol. 1995 Mar;114(6):1110–1116. doi: 10.1111/j.1476-5381.1995.tb13322.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Frelin C., Guedin D. Why are circulating concentrations of endothelin-1 so low? Cardiovasc Res. 1994 Nov;28(11):1613–1622. doi: 10.1093/cvr/28.11.1613. [DOI] [PubMed] [Google Scholar]
  9. Fukuroda T., Noguchi K., Tsuchida S., Nishikibe M., Ikemoto F., Okada K., Yano M. Inhibition of biological actions of big endothelin-1 by phosphoramidon. Biochem Biophys Res Commun. 1990 Oct 30;172(2):390–395. doi: 10.1016/0006-291x(90)90685-g. [DOI] [PubMed] [Google Scholar]
  10. Gardiner S. M., Compton A. M., Kemp P. A., Bennett T. The effects of phosphoramidon on the regional haemodynamic responses to human proendothelin [1-38] in conscious rats. Br J Pharmacol. 1991 Aug;103(4):2009–2015. doi: 10.1111/j.1476-5381.1991.tb12368.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Haynes W. G., Webb D. J. Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet. 1994 Sep 24;344(8926):852–854. doi: 10.1016/s0140-6736(94)92827-4. [DOI] [PubMed] [Google Scholar]
  12. Hemsén A., Pernow J., Lundberg J. M. Regional extraction of endothelins and conversion of big endothelin to endothelin-1 in the pig. Acta Physiol Scand. 1991 Mar;141(3):325–334. doi: 10.1111/j.1748-1716.1991.tb09088.x. [DOI] [PubMed] [Google Scholar]
  13. Hexum T. D., Hoeger C., Rivier J. E., Baird A., Brown M. R. Characterization of endothelin secretion by vascular endothelial cells. Biochem Biophys Res Commun. 1990 Feb 28;167(1):294–300. doi: 10.1016/0006-291x(90)91764-j. [DOI] [PubMed] [Google Scholar]
  14. Howard P. G., Plumpton C., Davenport A. P. Anatomical localization and pharmacological activity of mature endothelins and their precursors in human vascular tissue. J Hypertens. 1992 Nov;10(11):1379–1386. doi: 10.1097/00004872-199211000-00010. [DOI] [PubMed] [Google Scholar]
  15. Ikegawa R., Matsumura Y., Tsukahara Y., Takaoka M., Morimoto S. Phosphoramidon, a metalloproteinase inhibitor, suppresses the secretion of endothelin-1 from cultured endothelial cells by inhibiting a big endothelin-1 converting enzyme. Biochem Biophys Res Commun. 1990 Sep 14;171(2):669–675. doi: 10.1016/0006-291x(90)91198-2. [DOI] [PubMed] [Google Scholar]
  16. Ikura T., Sawamura T., Shiraki T., Hosokawa H., Kido T., Hoshikawa H., Shimada K., Tanzawa K., Kobayashi S., Miwa S. cDNA cloning and expression of bovine endothelin converting enzyme. Biochem Biophys Res Commun. 1994 Sep 30;203(3):1417–1422. doi: 10.1006/bbrc.1994.2343. [DOI] [PubMed] [Google Scholar]
  17. Kitamura K., Yukawa T., Morita S., Ichiki Y., Eto T., Tanaka K. Distribution and molecular form of immunoreactive big endothelin-1 in porcine tissue. Biochem Biophys Res Commun. 1990 Jul 31;170(2):497–503. doi: 10.1016/0006-291x(90)92119-k. [DOI] [PubMed] [Google Scholar]
  18. Laporte S., Denault J. B., D'Orléans-Juste P., Leduc R. Presence of furin mRNA in cultured bovine endothelial cells and possible involvement of furin in the processing of the endothelin precursor. J Cardiovasc Pharmacol. 1993;22 (Suppl 8):S7–10. doi: 10.1097/00005344-199322008-00004. [DOI] [PubMed] [Google Scholar]
  19. Maguire J. J., Davenport A. P. ETA receptor-mediated constrictor responses to endothelin peptides in human blood vessels in vitro. Br J Pharmacol. 1995 May;115(1):191–197. doi: 10.1111/j.1476-5381.1995.tb16338.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. McMahon E. G., Palomo M. A., Moore W. M. Phosphoramidon blocks the pressor activity of big endothelin[1-39] and lowers blood pressure in spontaneously hypertensive rats. J Cardiovasc Pharmacol. 1991;17 (Suppl 7):S29–S33. doi: 10.1097/00005344-199100177-00009. [DOI] [PubMed] [Google Scholar]
  21. Molenaar P., O'Reilly G., Sharkey A., Kuc R. E., Harding D. P., Plumpton C., Gresham G. A., Davenport A. P. Characterization and localization of endothelin receptor subtypes in the human atrioventricular conducting system and myocardium. Circ Res. 1993 Mar;72(3):526–538. doi: 10.1161/01.res.72.3.526. [DOI] [PubMed] [Google Scholar]
  22. Mombouli J. V., Le S. Q., Wasserstrum N., Vanhoutte P. M. Endothelins 1 and 3 and big endothelin-1 contract isolated human placental veins. J Cardiovasc Pharmacol. 1993;22 (Suppl 8):S278–S281. doi: 10.1097/00005344-199322008-00073. [DOI] [PubMed] [Google Scholar]
  23. Murphy L. J., Corder R., Mallet A. I., Turner A. J. Generation by the phosphoramidon-sensitive peptidases, endopeptidase-24.11 and thermolysin, of endothelin-1 and c-terminal fragment from big endothelin-1. Br J Pharmacol. 1994 Sep;113(1):137–142. doi: 10.1111/j.1476-5381.1994.tb16185.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Ohnaka K., Takayanagi R., Ohashi M., Nawata H. Conversion of big endothelin isopeptides to mature endothelin isopeptides by cultured bovine endothelial cells. J Cardiovasc Pharmacol. 1991;17 (Suppl 7):S17–S19. doi: 10.1097/00005344-199100177-00006. [DOI] [PubMed] [Google Scholar]
  25. Opgenorth T. J., Wu-Wong J. R., Shiosaki K. Endothelin-converting enzymes. FASEB J. 1992 Jun;6(9):2653–2659. doi: 10.1096/fasebj.6.9.1612289. [DOI] [PubMed] [Google Scholar]
  26. Pernow J., Hemsén A., Lundberg J. M., Nowak J., Kaijser L. Potent vasoconstrictor effects and clearance of endothelin in the human forearm. Acta Physiol Scand. 1991 Mar;141(3):319–324. doi: 10.1111/j.1748-1716.1991.tb09087.x. [DOI] [PubMed] [Google Scholar]
  27. Plumpton C., Champeney R., Ashby M. J., Kuc R. E., Davenport A. P. Characterization of endothelin isoforms in human heart: endothelin-2 demonstrated. J Cardiovasc Pharmacol. 1993;22 (Suppl 8):S26–S28. doi: 10.1097/00005344-199322008-00009. [DOI] [PubMed] [Google Scholar]
  28. Plumpton C., Kalinka S., Martin R. C., Horton J. K., Davenport A. P. Effects of phosphoramidon and pepstatin A on the secretion of endothelin-1 and big endothelin-1 by human umbilical vein endothelial cells: measurement by two-site enzyme-linked immunosorbent assays. Clin Sci (Lond) 1994 Aug;87(2):245–251. doi: 10.1042/cs0870245. [DOI] [PubMed] [Google Scholar]
  29. Sawamura T., Kimura S., Shinmi O., Sugita Y., Yanagisawa M., Masaki T. Analysis of endothelin related peptides in culture supernatant of porcine aortic endothelial cells: evidence for biosynthetic pathway of endothelin-1. Biochem Biophys Res Commun. 1989 Aug 15;162(3):1287–1294. doi: 10.1016/0006-291x(89)90813-9. [DOI] [PubMed] [Google Scholar]
  30. Schmidt M., Kröger B., Jacob E., Seulberger H., Subkowski T., Otter R., Meyer T., Schmalzing G., Hillen H. Molecular characterization of human and bovine endothelin converting enzyme (ECE-1). FEBS Lett. 1994 Dec 19;356(2-3):238–243. doi: 10.1016/0014-5793(94)01277-6. [DOI] [PubMed] [Google Scholar]
  31. Shimada K., Takahashi M., Tanzawa K. Cloning and functional expression of endothelin-converting enzyme from rat endothelial cells. J Biol Chem. 1994 Jul 15;269(28):18275–18278. [PubMed] [Google Scholar]
  32. Skolovsky M., Galron R., Kloog Y., Bdolah A., Indig F. E., Blumberg S., Fleminger G. Endothelins are more sensitive than sarafotoxins to neutral endopeptidase: possible physiological significance. Proc Natl Acad Sci U S A. 1990 Jun;87(12):4702–4706. doi: 10.1073/pnas.87.12.4702. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Suzuki N., Matsumoto H., Kitada C., Kimura S., Miyauchi T., Fujino M. A sandwich-type enzyme immunoassay to detect immunoreactive big-endothelin-1 in plasma. J Immunol Methods. 1990 Mar 9;127(2):165–170. doi: 10.1016/0022-1759(90)90065-4. [DOI] [PubMed] [Google Scholar]
  34. Turner A. J. Endothelin-converting enzymes and other families of metallo-endopeptidases. Biochem Soc Trans. 1993 Aug;21(3):697–701. doi: 10.1042/bst0210697. [DOI] [PubMed] [Google Scholar]
  35. Watanabe Y., Naruse M., Monzen C., Naruse K., Ohsumi K., Horiuchi J., Yoshihara I., Kato Y., Nakamura N., Kato M. Is big endothelin converted to endothelin-1 in circulating blood? J Cardiovasc Pharmacol. 1991;17 (Suppl 7):S503–S505. doi: 10.1097/00005344-199100177-00143. [DOI] [PubMed] [Google Scholar]
  36. Weitzberg E., Ahlborg G., Lundberg J. M. Long-lasting vasoconstriction and efficient regional extraction of endothelin-1 in human splanchnic and renal tissues. Biochem Biophys Res Commun. 1991 Nov 14;180(3):1298–1303. doi: 10.1016/s0006-291x(05)81336-1. [DOI] [PubMed] [Google Scholar]
  37. Xu D., Emoto N., Giaid A., Slaughter C., Kaw S., deWit D., Yanagisawa M. ECE-1: a membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1. Cell. 1994 Aug 12;78(3):473–485. doi: 10.1016/0092-8674(94)90425-1. [DOI] [PubMed] [Google Scholar]
  38. Yanagisawa M., Kurihara H., Kimura S., Tomobe Y., Kobayashi M., Mitsui Y., Yazaki Y., Goto K., Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988 Mar 31;332(6163):411–415. doi: 10.1038/332411a0. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES